Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

製品コードS2680

CAS No. 936563-96-1

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

サイズ

価格(税別)

10mM (1mL in DMSO)	JPY 47100
5mg	JPY 30200
50mg	JPY 163000
200mg	JPY 412000

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297|電子メール：[email protected]|よく尋ねられる質問

文献中Selleckの製品使用例(447)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

製品説明

ターゲット

BTK ^[1] (Cell-free assay)	BLK ^[1] (Cell-free assay)	Bmx ^[1] (Cell-free assay)	CSK ^[1] (Cell-free assay)	FGR ^[1] (Cell-free assay)	もっとクリックする
0.5 nM	0.5 nM	0.8 nM	2.3 nM	2.3 nM	もっとクリックする

体外試験

Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. ^[1] Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling. ^[2] A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2.6 nM, 0.5 nM and 3.9 nM, respectively. ^[3]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human Rec1 cells	MlzQSpVv[3Srb36gZZN{[Xl?	MoK2Nk42KM7:TR?=	MmHDOkBp	NE[wV5dKdmirYnn0bY9vKG:oIFz5ckBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gVoVkOSClZXzsd{BifCB{LkWgeW0hcW6ldXLheIVlKG[xcjC2JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIH3leIhw\A>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{Mki3O{c,OjV{MkK4O\|c9N2F-
human WSU-NHL cells	M2Xa[GN6fG:2b4jpZ:Kh[XO\|YYm=		NHnVfY84OiCq	NFfBSVBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBYW1VvTljMJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFkh\|ryP	NU\kXXR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
human SU-DHL6 cells	M2nMb2N6fG:2b4jpZ:Kh[XO\|YYm=		M4nxZlczKGh?	Mk[yR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3UuTEiONjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW4JO69VS5?	NYj5N\|k1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
human DOHH2 cells	M{PERWN6fG:2b4jpZ:Kh[XO\|YYm=		NF7oSZI4OiCq	MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEU2hJOiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDseY1qdmW\|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzIN88UU4>	NGP2NXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 cells	MnOxSpVv[3Srb36gZZN{[Xl?		MYKxJIg>	MnHRTY5pcWKrdHnvckBw\iCOWV6tRUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHHmeIVzKDZyIH3pcpMh[nliVGKtSnJGXCCDc4PhfUwhUUN3ME2wMlIh\|ryPLh?=	NEnZc5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1PFU1Pyd-MkG5OVg2PDd:L3G+
human Ramos cells	NIjweW1HfW6ldHnvckBie3OjeR?=		M1LpZVEhcA>?	M1G0NGlvcGmkaYTpc44hd2ZiQoTrJIlvKGi3bXHuJHJidW:\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhWEyFLXfhcY1iOiCyaH;zdIhwenmuYYTpc44h[XRiVInyNVIyPyCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyxiSVO1NF0yPCCwTT6=	M1vRdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
human Pfeiffer cells	MWTGeY5kfGmxbjDhd5NigQ>?		NUC1N5EzPzJiaB?=	NVfiN214S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWG[naX\m[ZIh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NkBvVS5?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
Sf9 cells	MmLKSpVv[3Srb36gZZN{[Xl?		MmqxNUBp	MWDJcohq[mm2aX;uJI9nKGi3bXHuJIZ2dGxvbHXu[5RpKEKWSzDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KHW\|aX7nJGZCVS2VcnP0bYRmKHCncITp[IUh[XNic4Xid5Rz[XSnIHHmeIVzKDZyIH3pcpMh[nliVGKtSnJGXCCDc4Phfg+9lCCLQ{WwQVAvPSCwTT6=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3OEW0O{c,OjF7NUi1OFc9N2F-
Sf9 insect cells	MXPGeY5kfGmxbjDhd5NigQ>?		MWW2NEBucW6\|	MYnJR\|UxKD1iMD6wNFA{KM7:TR?=	NV\YN4Z3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFYyOzZpPkK5NVQ3OTN4PD;hQi=>
sf9 cells	M3nMbGZ2dmO2aX;uJIF{e2G7			MVrJR\|UxKD1iMD6wNFA{KM7:TR?=	NYD3OXFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzZpPkK3PVk1PzN4PD;hQi=>
Sf9 insect cells	NW\RN3JWTnWwY4Tpc44h[XO\|YYm=		M3qyTlYxKG2rboO=	MXXJR\|UxKD1iMD6wNFA{PCEQvF2=	M3rmflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Sf9 insect cells	NYPVUHg4TnWwY4Tpc44h[XO\|YYm=		NIGyO5Q3OCCvaX7z	MV7JR\|UxKD1iMD6wNFA{PCEQvF2=	MmPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{K5OFYoRjJ6NEOyPVQ3RC:jPh?=
Sf9 insect cells	NYHodHdjTnWwY4Tpc44h[XO\|YYm=		NVXIVZBrPjBibXnudy=>	NFXVVZpKSzVyIE2gNE4xODB\|NDFOwG0>	NV33b2ZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5OVYxOzdpPkK3PVU3ODN5PD;hQi=>
Sf9 cells	NULrboZZTnWwY4Tpc44h[XO\|YYm=		NH\4WYM3OCCvaX7z	MlLZTWM2OCB;IECuNFAxPCEQvF2=	NEOwbXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
Sf9 cells	M4nLUGZ2dmO2aX;uJIF{e2G7		NEfJNWI3OCCvaX7z	M4HDR2lEPTBiPTCwMlAxODVizszN	MmmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUi1OFcoRjJzOUW4OVQ4RC:jPh?=
Ramos cells	MX;GeY5kfGmxbjDhd5NigQ>?		M{\kU\|EhcA>?	M{LkSGlEPTBiPTCwMlAxODVizszN	NEPHZoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
Sf9 cells	MkX5SpVv[3Srb36gZZN{[Xl?		M1jwOlYxKG2rboO=	MV7JR\|UxKD1iMD6wNFEh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
Pfeiffer cells	NIq2[ZpEgXSxdH;4bYNqfHliYYPzZZk>		M3zT[\|czKGh?	MWLHTVUxKD1iMD6wNFIh\|ryP	NEfDcpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
B cells	NGjvWJRHfW6ldHnvckBie3OjeR?=		M4fPWFEhcA>?	M3LMdmlEPTBiPTCwMlAxPDZizszN	NIG4SJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK5NFk5QCd-M{CyPVA6QDh:L3G+
Sf9 insect cells	NVPwNplPTnWwY4Tpc44h[XO\|YYm=		M{LpPFIhfG9iNkCgcYlvew>?	M3LEZWtqKD1iMD6wNFQ5KM7:TR?=	M3PGbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
Ramos cells	NV;oN2N1TnWwY4Tpc44h[XO\|YYm=		MWSxJIg>	M2i4PGlEPTBiPTCwMlAxPzVizszN	NWL0XG5{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 insect cells	MUHGeY5kfGmxbjDhd5NigQ>?		NGPuRok3OCCvaX7z	MU\JR\|UxKD1iMD6wNFgh\|ryP	NWP0[3lWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N\|E2PTl5PD;hQi=>
TMD8 cells	M1zYO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M1X5NlczKGh?	Mn23TWM2OCB;IECuNFEh\|ryP	M3f3ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{G1NFI{Lz5{OUexOVAzOzxxYU6=
CD19+ B cells	NYXvZYR5TnWwY4Tpc44h[XO\|YYm=		MVyxJIg>	NUX3TYREUUN3MDC9JFAvODF{IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3N{m4Nkc,Ojl2NUe5PFI9N2F-
Sf9 insect cells	MlrXSpVv[3Srb36gZZN{[Xl?		NH74NmQ3OCCvaX7z	NEC1[G5KSzVyIE2gNE4xOTJizszN	NGjSR\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells	MYfGeY5kfGmxbjDhd5NigQ>?		NHjyV3MyKGh?	NWDzW4xMUUN3MDC9JFAvODF2IN88US=>	MnLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
Sf9 insect cells	MoX6SpVv[3Srb36gZZN{[Xl?		MojlNUBp	MXPJR\|UxKD1iMD6wNVQ1KM7:TR?=	NUjy[JVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3NVUxOjNpPkK5O\|E2ODJ\|PD;hQi=>
Sf9 insect cells	NHiwdGlHfW6ldHnvckBie3OjeR?=		M{nEfVYxKG2rboO=	NHfafmpKSzVyIE2gNE4xOTZzIN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN\|Y9N2F-
HCC827 cells	MoXlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NF32VGk4OiCq	NVyxXY85UUN3MDC9JFAvODN7IN88US=>	M3;ZblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{O0OVgyLz5{OEezOFU5OTxxYU6=
PC9 cells	M33NS2Z2dmO2aX;uJIF{e2G7		Mke3O\|IhcA>?	MYTHTVUxKD1iMD6wOUDPxE1?	Mln0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
Sf9 cells	NVzzSYNSTnWwY4Tpc44h[XO\|YYm=		MVi2NEBucW6\|	MmPNTWM2OCB;IECuNUDPxE1?	NGG5cos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
H3255 cells	M4i4XGZ2dmO2aX;uJIF{e2G7		NF2wVGg4OiCq	MUPHTVUxKD1iMD6xNUDPxE1?	NXHFbmZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BaF3 cells	M3jBfWZ2dmO2aX;uJIF{e2G7		M{HsPFczKGh?	NH3EbodIUTVyIE2gNE4yOiEQvF2=	Mkf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4M{C1OVMoRjJ4NkOwOVU{RC:jPh?=
BAF3 cells	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NVnMNW9nPzJiaB?=	MVXHTVUxKD1iMD6xNkDPxE1?	M2rUXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
Sf9 insect cells	MUnGeY5kfGmxbjDhd5NigQ>?		MVK2NEBucW6\|	NWHnPHBMUUN3MDC9JFAvOTJ\|IN88US=>	M4rkUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
Sf9 insect cells	MoTPSpVv[3Srb36gZZN{[Xl?		MVW2NEBucW6\|	NXjxXWRSUUN3MDC9JFAvOTR4IN88US=>	MnjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
BAF3 cells	MXXGeY5kfGmxbjDhd5NigQ>?		NXuzWY9sPzJiaB?=	NX\qTZhqT0l3MDC9JFAvOTZizszN	NWC3Z5B{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
Sf9 cells	NWHmW5I2TnWwY4Tpc44h[XO\|YYm=		NF:4ZVU3OCCvaX7z	NF\FZWhKSzVyIE2gNE4zKM7:TR?=	MnHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUi1OFcoRjJzOUW4OVQ4RC:jPh?=
MV411 cells	M4\QS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			Ml[xS2k2OCB;IECuNlUh\|ryP	M1PGbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
MV4-11 cells	MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MlzGO\|IhcA>?	NYfqVWFuT0l3MDC9JFAvOzNizszN	NXT5SnZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2N\|A2PTNpPkK2OlMxPTV\|PD;hQi=>
MV4-11 cells	M1;PO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NGD3S5I4OiCq	M3W5VmdKPTBiPTCwMlM{KM7:TR?=	MmnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
DOHH2 cells	NFnzTZdEgXSxdH;4bYNqfHliYYPzZZk>		NYjodm17PzJiaB?=	M3PwVWdKPTBiPTCwMlQyKM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
HCC827 cells	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NVvJToNEQTZiaB?=	M{jaRWVEPTBiPTCwMlQ2KM7:TR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
SU-DHL6 cells	MX3DfZRwfG:6aXPpeJkh[XO\|YYm=		M3HF[FczKGh?	NVOzVXdzT0l3MDC9JFAvPThizszN	NV3XfFR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
M07e cells	NX\scHFST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			Ml3zS2k2OCB;IECuOVkh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
NCI-H1975 cells	NXfz[ZhQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MVO5OkBp	NHPh[lRGSzVyIE2gNE43PCEQvF2=	NYLabotQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
SU-DHL-2 cells	MnPlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NI[zeFRIUTVyIE2gNE43PCEQvF2=	MmTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
HEK293T cells	MmjwSpVv[3Srb36gZZN{[Xl?		MW[xJIg>	NGXlXINKSzVyIE2gNE46KM7:TR?=	M{Ppb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiwNlYyLz5{OEK4NFI3OTxxYU6=
Ramos cells	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M2faOlczKGh?	M3XINGlEPTBiPTCwMlkzKM7:TR?=	NGC5OXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUexOVAzOyd-Mkm3NVUxOjN:L3G+
BA/F3 cells	NVvvT2tESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M4LFRVczKGh?	M13SbGlEPTBiPTCxJO69VQ>?	M1m5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
WSU-NHL cells	M4Loc2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M2LY[\|czKGh?	MWPHTVUxKD1iMT6wPUDPxE1?	NU\NZXlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
NCI-H1975 cells	NH:5folHfW6ldHnvckBie3OjeR?=		M2TDNFczKGh?	NXjZeohxT0l3MDC9JFEvOiEQvF2=	MoPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975 cells	NYHucGZjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M4HqNlczKGh?	NUDOVFU2UUN3MDC9JFEvOjdizszN	NYHj[HNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3N\|Q2QDFpPkK4O\|M1PThzPD;hQi=>
Raji cells	MkXiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M4HxUFQ5KGh?	NXHRT3BnUUN3MDC9JFEvPDlizszN	NYrFNWNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OlczQTVpPkK5OVY4Ojl3PD;hQi=>
Pfeiffer cells	MkLMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M{j2dWdKPTBiPTCxMlYh\|ryP	NHrUdXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
A431 cells	MlfzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NIH3XVU6PiCq	MmTLSWM2OCB;IEKuN\|gh\|ryP	NEKxXJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
BAF3 cells	NYHtc3VJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MnrUO\|IhcA>?	MoHnS2k2OCB;IEKuOUDPxE1?	NYLWZ4hHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
U937 cells	MoHXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NHm0e41IUTVyIE2gNk46KM7:TR?=	NHvndFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
NB4 cells	MmX0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NVzVenp1T0l3MDC9JFMh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
Ramos cells	MoX4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NYewcZhvT0l3MDC9JFMvPCEQvF2=	M{HQclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
SKM1 cells	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M4X2RWdKPTBiPTCzMlYh\|ryP	MlHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
U2932 cells	MkjlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MU\HTVUxKD1iND60JO69VQ>?	NHXNenk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells	M{i0b2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M4XYd\|czKGh?	NVvRcYlmUUN3MDC9JFUvOTRizszN	M3PNW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEC2NVQ{Lz5\|MECwOlE1OzxxYU6=
Ramos cells	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		Mle2OFghcA>?	M4PZR2lEPTBiPTC1MlE1KM7:TR?=	M1;kTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUW2NFM4Lz5{N{m1OlA{PzxxYU6=
Ramos cells	NHnsVHlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M1PR[lQ5KGh?	NIizRZdKSzVyIE2gOU45QCEQvF2=	MmnQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{K5OFYoRjJ6NEOyPVQ3RC:jPh?=
Ramos cells	M4ex[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M2fWdVczKGh?	NXjQN2VjUUN3MDC9JFYvPjJizszN	NF32cHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlE{Pid-MkmxOFYyOzZ:L3G+
K562 cells	MlOwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NF63fmQ1QCCq	NVzh[GFbUUN3MDC9JFcvPSEQvF2=	NGTjdGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3O\|YxQCd-M{CwO\|c3ODh:L3G+
HL60 cells	M2Lrd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NVnnWG9HPDhiaB?=	NGTaWo9KSzVyIE2gPEDPxE1?	M1PxeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5\|MEC3O\|YxQDxxYU6=
Ramos cells	Ml6yRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MlLMOFghcA>?	NFnJT5JKSzVyIE2gPE4yOSEQvF2=	MmLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|YoRjJ5OUm0O\|M3RC:jPh?=
Ramos cells	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NHe5S4k1QCCq	MYfJR\|UxKD1iOD6yOkDPxE1?	MmrwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NkeyPVUoRjJ7NU[3Nlk2RC:jPh?=
OCI-AML3 cells	NITNb41Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MlfsS2k2OCB;IEmuNkDPxE1?	NVzaWYVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N\|E2PTl5PD;hQi=>
BAF3 cells	NHf6TmlEgXSxdH;4bYNqfHliYYPzZZk>		M1n1OlczKGh?	MlTCS2k2OCB;IEGwJO69VQ>?	M3PwelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkOwOVU{Lz5{Nk[zNFU2OzxxYU6=
BAF3 cells	Mk[1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NYjXXlQ6PzJiaB?=	NHLJT2JIUTVyIE2gNVAh\|ryP	NIrvNpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3 cells	MoXsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MoXLO\|IhcA>?	NFLscXNIUTVyIE2gNVAh\|ryP	NFfWU5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NAMALWA cells	NILibVNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M2TQZ\|czKGh?	NUDLVmxQUUN3MDC9JFExNjR3IN88US=>	M3zPRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
Ramos cells	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NI\SeHA1QCCq	MWfJR\|UxKD1iMUKuOkDPxE1?	M{DZcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Raji cells	MmHaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NWfBNWxyPDhiaB?=	MWXJR\|UxKD1iMUSuNkDPxE1?	NFS0TII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3O\|YxQCd-M{CwO\|c3ODh:L3G+
Raji cells	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NVTtdoprPDhiaB?=	NWXONnhoUUN3MDC9JFE2NjJizszN	MkHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|YoRjJ5OUm0O\|M3RC:jPh?=
MIAPaCa2 cells	MlTQR5l1d3SxeHnjbZR6KGG\|c3H5		NYDqWopuOyCmYYnz	MnGyTWM2OCB;IEG2MlYh\|ryP	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
HeLa cells	MULDfZRwfG:6aXPpeJkh[XO\|YYm=		M32zblMh\GG7cx?=	M4\4RWlEPTBiPTCxOk45KM7:TR?=	M3PU[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEe3NlI5Lz5{N{C3O\|IzQDxxYU6=
Raji cells	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NXL4XGNbPDhiaB?=	M2XPeWlEPTBiPTCxPU4{KM7:TR?=	MlGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUKxO\|UoRjJ5OUGyNVc2RC:jPh?=
Raji cells	M37sVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M3j0bFQ5KGh?	Mof5TWM2OCB;IEG5MlMh\|ryP	NHLzVXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNlk1Pid-Mki0N\|I6PDZ:L3G+
Raji cells	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		Mk\IO\|IhcA>?	NW\WTWc1UUN3MDC9JFE6NjVizszN	M3fuSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEC2NVQ{Lz5\|MECwOlE1OzxxYU6=
Raji cells	M2nHOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M3Tm[lQ5KGh?	NIr3dldKSzVyIE2gNVkvPSEQvF2=	NULGUlQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5OVYxOzdpPkK3PVU3ODN5PD;hQi=>
NAMALWA cells	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MYO3NkBp	MV3JR\|UxKD1iMUmuOkDPxE1?	NWe3dXA6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR\|PD;hQi=>
A2780 cells	NUDqe3FQS3m2b4TvfIlkcXS7IHHzd4F6		MluzN{Bl[Xm\|	MmWwSWM2OCB;IEKwMlEh\|ryP	M4C3XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEe3NlI5Lz5{N{C3O\|IzQDxxYU6=
Raji cells	M1j6eGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NXTU[ZBoPzJiaB?=	NWTWbo1yUUN3MDC9JFIxNjh6IN88US=>	M2L6OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
A549 cells	NICzTmhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M3XiW\|czKGh?	MU\JR\|UxKD1iMkGuO\|kh\|ryP	NYXWNm9ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3N\|Q2QDFpPkK4O\|M1PThzPD;hQi=>
SW480 cells	M2nQbmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NYrMUodOOyCmYYnz	NEP5b\|ZKSzVyIE2gNlUvPiEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
Ramos cells	MmL5R5l1d3SxeHnjbZR6KGG\|c3H5		NIDWdnEzPCCq	MoLtTWM2OCB;IEK4Mlch\|ryP	NGO2O5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK3OFY4PSd-MkiyO\|Q3PzV:L3G+

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	pEGFR(Tyr1068) / EGFR; PubMed: 28061447 Oncotarget Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment. pBTK / pPLCγ2 / pAKT / pERK / pJNK; PubMed: 23940282 Blood Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.	28061447 23940282
Immunofluorescence	CD11b; PubMed: 30231870 J Neuroinflammation BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm. COX-2; PubMed: 30231870 J Neuroinflammation BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies.	30231870
ELISA	hTNFα; PubMed: 26627823 J Biol Chem PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3). IL-10; PubMed: 27792904 Virology LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.	26627823 27792904

体内試験

In a collagen-induced arthritis model, Ibrutinib significantly reduces clinical arthritis scores reflecting paw swelling and joint inflammation by inhibiting B-cell activation. In a MRL-Fas(lpr) lupus model, Ibrutinib reduces renal disease and autoantibody production. ^[1] In an adoptive transfer TCL1 mouse model of CLL, Ibrutinib (25 mg/kg/day) causes a transient early lymphocytosis, and delays CLL disease progression. ^[4]

お薦めの試験操作（参考用のみ）

キナーゼ試験： ^[1]	- 合併 Kinase Assays : In vitro kinase IC50 values are measured using ³³P filtration binding assay after 1 hour incubation of kinase, ³³P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology.
細胞試験： ^[2]	- 合併細胞株： Chronic lymphocytic leukemia (CLL) cells 濃度： 0.01-100 μM 反応時間： 48 hours 実験の流れ： MTT (3'[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assays are performed to determine cytotoxicity. Briefly, cells (CLL B cells or healthy volunteer T cells or NK cells) are incubated for 48 hours with different concentrations of Ibrutinib, or vehicle control. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. Dimethyl sulfoxide is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed with Expo-ADC32 software package. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis includes the addition of 100μM Z-VAD. (参考用のみ)
動物試験： ^[1]	- 合併動物モデル： MRL-Fas(lpr) lupus model and collagen-induced arthritis model. 投薬量： ≤50 mg/kg 投与方法： Administered via p.o. (参考用のみ)

参考

[4] Ponader S, et al. Blood. 2012, 119(5), 1182-1189.

- 合併

溶解度 (25°C)

体外	DMSO	88 mg/mL (199.77 mM)
	Ethanol	45 mg/mL (102.15 mM)
	Water	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O 混合させたのち直ちに使用することを推奨します。	10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Ibrutinib (PCI-32765) SDFをダウンロードする

分子量	440.5
化学式	C₂₅H₂₄N₆O₂
CAS No.	936563-96-1
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	N/A
Smiles	C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04876092	Recruiting	Drug: JNJ-67856633\|Drug: Ibrutinib	Leukemia Lymphocytic Chronic B-Cell\|Lymphoma Non-Hodgkin	Janssen Research & Development LLC	July 28 2021	Phase 1
NCT04665115	Not yet recruiting	Drug: Ibrutinib\|Other: Quality-of-Life Assessment	Asymptomatic COVID-19 Infection Laboratory-Confirmed\|B-Cell Neoplasm\|Chronic Lymphocytic Leukemia\|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma\|Mantle Cell Lymphoma\|Marginal Zone Lymphoma\|Small Lymphocytic Lymphoma\|Symptomatic COVID-19 Infection Laboratory-Confirmed\|Waldenstrom Macroglobulinemia	Academic and Community Cancer Research United\|National Cancer Institute (NCI)	June 30 2021	Phase 2
NCT04294641	Recruiting	Drug: Ibrutinib	Chronic GVHD	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	May 10 2021	Phase 2
NCT04514393	Not yet recruiting	Drug: Methotrexate\|Drug: Ibrutinib\|Drug: Temozolomide	Primary Central Nervous System Lymphoma\|PCNSL\|Non Hodgkin Lymphoma	Huiqiang Huang\|Guangdong 999 Brain Hospital\|Nanfang Hospital of Southern Medical University\|Xian-Janssen Pharmaceutical Ltd.\|Sun Yat-sen University	December 1 2020	Phase 2
NCT03679624	Recruiting	Drug: Ibrutinib\|Drug: Daratumumab	Waldenstrom Macroglobulinemia\|Waldenstrom''s Disease\|Waldenström; Hypergammaglobulinemia\|Waldenstrom''s Macroglobulinemia Recurrent\|Waldenstrom''s Macroglobulinemia of Lymph Nodes\|Waldenstrom''s Macroglobulinaemia Without Mention of Remission\|Waldenstrom''s Macroglobulinemia Refractory	Weill Medical College of Cornell University\|Janssen Scientific Affairs LLC\|Mayo Clinic	July 30 2020	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

よくある質問（FAQ）

質問1：
How to reconstitute the compound S2680 for in vivo studies?
回答：
For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

研究分野別

製品類型

Ibrutinib (PCI-32765)

文献中Selleckの製品使用例(447)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Ibrutinib (PCI-32765) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技術サポート

よくある質問（FAQ）